Drug intelligence / Profile preview

structolipid

Development stage: Unknown
Lead developer: Fresenius Kabi
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

Structolipid is a 20% lipid emulsion used in parenteral nutrition therapy. It contains structured triglycerides where both medium-chain and long-chain fatty acids are esterified to the same glycerol backbone, unlike conventional lipid emulsions that contain either pure long-chain triglycerides or physical mixtures of medium and long-chain triglycerides. This unique structure is designed to improve lipid utilization and metabolism in patients requiring parenteral nutrition.

Brand names: Structolipid

Beyond the preview

Go deeper on structolipid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on structolipid.

Explore the full profile